Price T Rowe Associates Inc Tango Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 15,234 shares of TNGX stock, worth $128,117. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,234
Previous 12,771
19.29%
Holding current value
$128,117
Previous $102,000
28.43%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TNGX
# of Institutions
119Shares Held
89.1MCall Options Held
2.6KPut Options Held
1K-
Trv Gp Iv, LLC Boston, MA19.2MShares$161 Million81.48% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$112 Million4.04% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$69 Million3.91% of portfolio
-
Nextech Invest Ag5.53MShares$46.5 Million8.96% of portfolio
-
Southpoint Capital Advisors LP New York, NY5.28MShares$44.4 Million1.32% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $741M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...